We are a privately held, pre-commercial biotech company focused on the development and commercialization of a highly effective therapy for serious skin and soft tissue infections, including those caused by antibiotic-resistant organisms such as Methicillin-resistant Staphylococcus aureus (MRSA), based on a disruptive new drug delivery technology called Ultrasonic Drug Disperson (UDD).
Soft tissue infections are a major global health issue. When an inadequate concentration of antibiotic is used to treat a given infection, antibiotic resistant strains of bacteria develop that are increasingly difficult to treat. Patients with MRSA cellulitis of the lower extremity, especially those with impaired circulation, such as diabetics, are even more difficult to treat with standard delivery methods of antibiotics because an adequate concentration of antibiotic cannot be delivered to the target tissues.
Our current study demonstrates a new method to deliver antibiotics directly to the target tissue, independent of blood supply. Prior to this study, other than topical applications, antibiotics have always been given systemically either orally, intramuscularly (IM) or intravenously (IV). Sometimes an antibiotic must be given systemically because that is the only method to access the infection, for example, with pneumonia, meningitis, or a kidney infection. However, if the infection is located in soft tissue that is readily accessible, then direct delivery of antibiotics becomes a viable option.